Molecule intelOpportunity: ModerateEssential

Anastrozole

42 brands · 30 companies · product forms

ATC: L02BG03 1 DRAP alert

Opportunity snapshot

Launch attractiveness
39
Market saturation
78
Price room
100
Regulatory risk
40
42
brands
30
companies
Rs 9,654.33
median price
38
price points
15.78x
price spread
100
confidence %

Who competes here

Top companies by brand count — fragmented market (no dominant player) · leader share 7%

Price room

Across observed sources and strengths
CheapestRs 832.54
MedianRs 9,654.33
Most expensiveRs 13,136.02
Spread15.78×
Sources: DRAP-official, DVAGO, Servaid

max/min price ratio 15.78x across 38 trusted points (Rs 832.54-13136.02). NOTE: mixes strengths (graph prices carry no strength), so treat as indicative.

Brands & products on the market

Sample of 12 live products for Anastrozole — each links to its own medicine page.

Regulatory alerts

latest 2023-10-26
Drug Safety Alert: Risk of Tendon Disorders with Third-Generation Aromatase inhibitors

Why this score

Launch attractiveness

40% supply-gap(25) + 25% price-variation(100) + 20% low-competition(22) + 15% supply-disruption(0), damped by confidence(100). Higher = more attractive, less crowded opportunity.

Market saturation

30 canonical companies and 42 brands compete (saturation pegged at 30 companies / 150 brands).

Price room

max/min price ratio 15.78x across 38 trusted points (Rs 832.54-13136.02). NOTE: mixes strengths (graph prices carry no strength), so treat as indicative.

Regulatory risk

1 DRAP alert(s), latest 2023-10-26.

Confidence

Full coverage.

Packaged brief for this moderate opportunity?

Molecule page + company profiles + price-room analysis are the pilot package for pharma teams.

See packaged reports All 3868 molecules

Molecule intelligence as of 2026-07-30. Brand/company counts from DRAP registry and observed retail sources.

For medicine intelligence and professional reference only. Not medical advice.